Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | APP | P05067 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | S1PR1 | P21453 | 3/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22266264 | 0.96 | TSHR (0.33) | MEN1KMT2ATSHRMAPK1 | |
| SCHEMBL22266258 | 0.93 | TSHR (0.34) | MEN1KMT2ATSHRMAPK1 | |
| SCHEMBL22266268 | 0.90 | CYP1A2 (0.30) | — | |
| SCHEMBL22266282 | 0.86 | MEN1 (0.39) | MEN1KMT2ATSHRMAPK1APP | |
| SCHEMBL22266320 | 0.86 | CYP1A2 (0.32) | — | |
| SCHEMBL22266278 | 0.84 | HDAC3 (0.33) | — | |
| SCHEMBL20235114 | 0.84 | MAPK1 (0.37) | MEN1KMT2ATSHRMAPK1 | |
| SCHEMBL22266313 | 0.83 | HDAC3 (0.33) | — | |
| SCHEMBL22266274 | 0.83 | HDAC3 (0.33) | — | |
| SCHEMBL24761891 | 0.82 | CYP1A2 (0.32) | APPL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10723717-B2 | Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides | ARVINAS OPERATIONS, INC. (US) | 2020-07-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10723717-B2 | Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides | CRBN, ARAF, VHL | MEN1 2317/4885KMT2A 1975/4885TSHR 2304/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.